This is an aggregated industry headline. Read the full story at BioPharma Dive →
BridgeBio gets funding for drug launch; United buys into cell therapy
Elsewhere, Otsuka's kidney drug hit the goal of a confirmatory trial and Vertex's CRISPR sickle cell drug secured expanded approval.
By BioPharma Dive
· Jul 1, 2026
· via BioPharma Dive
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Contract manufacturing powerhouse Lonza is growing in more ways than one. The Swiss company revealed this week…
The WeekFierceBiotech ↗
United Therapeutics has paid $140 million to buy Thymmune Therapeutics for preclinical regenerative cell thera…
The WeekBriefing
China’s approval of a CAR‑T for solid tumors breaks a scientific barrier and raises pressure on U.S. developer…